Disease Overview：Psoriasis（PSO）
Psoriasis is a chronic, immune-mediated inflammatory skin disorder characterized by hyperproliferation of keratinocytes and dysregulated T-cell activity. Clinically, it manifests as well-demarcated, erythematous plaques with silvery scale—most commonly on extensor surfaces, scalp, and nails—though guttate, inverse, pustular, and erythrodermic variants also occur. The disease follows a relapsing-remitting course and is associated with significant comorbidities, including psoriatic arthritis (affecting up to 30% of patients), cardiovascular disease, metabolic syndrome, and depression. Diagnosis relies on clinical evaluation, supported by dermoscopy or skin biopsy when atypical. Treatment stratification depends on severity: topical corticosteroids and vitamin D analogs for mild disease; phototherapy (narrowband UVB, PUVA) and conventional systemic agents (methotrexate, cyclosporine) for moderate cases; and biologic therapies—including TNF-α inhibitors (adalimumab, infliximab), IL-17 inhibitors (secukinumab, ixekizumab), and IL-23 inhibitors (guselkumab, tildrakizumab)—for severe or refractory presentations.
China offers compelling advantages for psoriasis management: its dermatology centers—especially tier-3 hospitals in Beijing, Shanghai, and Guangzhou—boast internationally trained specialists with extensive experience in biologic therapy protocols and long-term disease monitoring. Advanced infrastructure includes state-of-the-art phototherapy units, digital dermoscopy systems, and on-site pharmacogenomic testing to guide biologic selection. Clinical outcomes align with global benchmarks: over 85% of moderate-to-severe patients achieve PASI 75 within 16 weeks on first-line biologics, with robust real-world data published in journals such as *The British Journal of Dermatology*. Crucially, treatment costs remain significantly lower than in the US or Western Europe—biologic regimens cost approximately 40–60% less, without compromising drug authenticity or regulatory oversight (all medications are NMPA-approved). As a dedicated medical tourism agency, we facilitate seamless international care: verifying hospital credentials, coordinating appointments with psoriasis-specialized dermatologists, providing itemized, transparent pricing in advance, arranging visa support, accommodation, and multilingual clinical liaison—all designed to reduce logistical uncertainty while prioritizing therapeutic continuity and safety.
Psoriasis: treatment in China helps patients compare specialist hospitals, initial assessment steps and estimated costs that may vary by city, institution and clinical condition.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Psoriasis (Dermatology)
Non-Surgical / Conservative / Medication-Based Therapy
*Target Criteria:* Mild-to-moderate plaque, guttate, or inverse psoriasis; stable comorbidities; no active infection or uncontrolled IBD.
- •Topical Therapy (First-line)
- *Vitamin D analogs (calcipotriol 0.005%)*: ¥120–¥220 ($17–$32) per 30g tube - *Combination topical (calcipotriol/betamethasone dipropionate)*: ¥260–¥420 ($38–$61) per 30g tube - *Initial dermatology consultation + skin exam*: ¥80–¥150 ($12–$22)
- •Systemic Oral Agents
- *Acitretin*: ¥160–¥320 ($23–$46)/month; baseline & quarterly liver/kidney panels: ¥220–¥350 ($32–$51) - *Apremilast*: ¥2,800–¥3,600 ($410–$525)/month (30-day supply)
- •Biologics (Subcutaneous)
- *Secukinumab (biosimilar)*: ¥2,100–¥2,700 ($307–$395)/dose (150 mg); loading phase (4 doses) + monthly maintenance - *Pre-biologic workup (HBV/HCV/HIV/TB testing, chest X-ray, CBC, LFTs, CRP)*: ¥480–¥720 ($70–$105)
Procedural / Phototherapy Options
*Eligibility:* Moderate-to-severe plaque/guttate psoriasis; phototherapy-naïve; no photosensitivity disorders or melanoma history.
- •Narrowband UVB (NB-UVB) Phototherapy
- *Standard course (24–36 sessions over 8–12 weeks)*: ¥2,400–¥5,200 ($350–$760) - *Pre-phototherapy skin assessment + eye protection fitting*: ¥100 ($15)
- •Excimer Laser (localized plaques)
- *Typical course (8–12 sessions)*: ¥1,800–¥3,600 ($265–$525)
Special/Complex Condition Management
- •*PsA-associated psoriasis:* TNF-α inhibitor (adalimumab) + rheumatology co-management: add ¥300–¥500 ($44–$73)/visit for joint ultrasound/MRI if indicated.
- •*Erythrodermic or generalized pustular psoriasis (GPP):* Hospital admission required; IV cyclosporine or infliximab initiation: ¥4,500–¥8,200 ($660–$1,200)/week (drug + monitoring + ICU-level nursing).
- •*Pediatric psoriasis (<12 years):* Topicals + NB-UVB only; biologics require pediatric dermatology approval: additional ¥200 ($29) consult fee.
Quick Selection Guide
- •Young adult, mild disease, budget-conscious: Topical calcipotriol + NB-UVB (total ~$400–$600 for 12 weeks).
- •Adult, moderate-severe, comorbid metabolic syndrome: Biosimilar secukinumab (lower hepatotoxicity vs. methotrexate); total first-year drug + monitoring ≈ $4,200–$5,800.
- •Elderly (>75), multiple comorbidities, frailty: Low-potency topical steroids + targeted excimer laser (avoids systemic exposure); total ~$800–$1,400.
- •Pregnancy planning or active pregnancy: Topical corticosteroids only; avoid all systemics/biologics; monthly dermatology follow-up ($12–$22/visit).
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Psoriasis Medical Vacation Packages
Curated transparent all-inclusive packages combining Psoriasis treatment with China top medical destinations:
